FEops Releases AI-Based Anatomical Analysis for HEARTguide

FEops has released its new FEops HEARTguide, which includes an artificial intelligence (AI)-based anatomical MSCT image analysis tool for pre-operative planning of structural heart interventions.
 
According to the company, by using this tool physicians aren’t required to do measurements manually to streamline workflow and save time. The tool is not black box, physicians are able to perform the analysis themselves.
 
Unique predictive simulations can show how transcatheter structural heart device will interact with anatomy before implantation. This can help to choose the best device size and position.
 
“We are staying ahead of the market with the introduction of this unique combination of predictive simulation and AI-enabled anatomical analysis,” Peter Mortier, Ph.D., co-founder and CTO of FEops told the press. “This extension of FEops HEARTguide enables a time efficient workflow for heart teams by providing them a fast, semi-automated and accurate anatomical analysis for efficient and standardized planning.”
 
Dr. Ian Buysschaert, St. Jan, Bruges, Belgium, added“The PRECISE-LAA trial results, presented earlier this week at CSI Frankfurt, confirm the positive impact of FEops HEARTguide on the decision process for LAAO interventions in daily clinical practice. The key value of FEops HEARTguide remains the simulation options predicting different sizes and positions, but the new DICOM interface will allow physicians to better visualize and edit the anatomical measurements, which is extremely useful for the operators.”
 
Matthieu De Beule Ph.D., co-founder and CEO of FEops continued: “FEops is on track to install the new standard in personalized treatment planning for structural heart interventions and brings us on the verge of global commercialization. With over 7000 patients treated worldwide in 327 hospitals spread over 28 countries, FEops is ready and uniquely positioned to extend its cloud-based platform outside of the structural heart space by leveraging its AI know-how, regulatory expertise, physician network and clinical footprint. This is putting us in pole position to extend our game-changing predictive digital twin offering to other applications with our upcoming Series C round.”
 
FEops HEARTguide was shown to significantly improve LAAC (left atrial appendage closure) procedures in a February 2023 study published in JACC: Cardiovascular Interventions.